To investigate the pharmacokinetics of once-daily saquinavir (SQV) hard-gelatin capsule (HGC)/ritonavir (RTV), 1600/100 mg, compared with once-daily SQV soft-gelatin capsule (SGC)/RTV, 1600/100 mg.
Although the use of saquinavir (SQV) along with other antiretroviral drugs to manage the effects of HIV infection has proved to be highly effective, the original formulation of SQV as a hard-gelatin capsule (HGC, Invirase) had limited bioavailability when used as the sole protease inhibitor (1) . Subsequent development of the soft-gelatin capsule (SGC, Fortovase) formulation increased bioavailability, mainly by the addition of the glyceride capmul, which improved the dissolution of the active drug in the small intestine (2, 3) . Ritonavir (RTV) has been shown to boost the levels of SQV by several processes (4) (5) (6) . Although there has been pharmacokinetic (PK) research on using once-daily SQV SGC at a dose of 1600 mg boosted with once-daily RTV at a dose of 100 mg, the data on the steady-state PK of 1600 mg of SQV HGC boosted with 100 mg of RTV once daily are lacking (7, 8) .
Disadvantages with the SQV SGC compound are the requirement for refrigeration, larger pill size, and increased gastrointestinal disturbance possibly caused by capmul in the formulation (9) . Although most subjects taking SQV are using the SGC formulation, subjects in the developing world could still potentially benefit from the use of the HGC formulation, which is stable at room temperature and has a lower cost. These characteristics make SQV HGC a more convenient and accessible medication with possible increased tolerability. We report on the PK of once-daily SQV SGC/RTV, 1600/100 mg, compared with once-daily SQV HGC/RTV, 1600/100 mg, both in combination with dual nucleoside reverse transcriptase inhibitors (NRTIs).
MATERIALS AND METHODS

Subjects and Study Design
Subjects were recruited from The Thai Red Cross Society's Anonymous STD/HIV screening clinic and the HIV outpatient immune clinic of King Chulalongkorn Memorial Hospital in Bangkok, Thailand. Before enrollment in the current study, these subjects were treated in various rollover protocols with SQV SGC and dual NRTIs (either Combivir [zidovudine (AZT)/lamivudine (3TC)] or didanosine [ddI]/stavudine [d4T] [1:1]) for more than 4 years. (7, 10, 11) . This cohort was then evaluated for a structured treatment interruption (STI) trial. The first 14 HIV-1-infected subjects who met the entry criteria of the STI trial (viral load <50 copies for more than 24 weeks and CD4 count >350 cells/mL) were randomly assigned to continue therapy with once-daily SQV SGC/RTV, 1600/100 mg, together with NRTIs and entered into this PK substudy. The study was approved by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University, and written informed consent was obtained from all subjects.
Pharmacokinetic Substudy
A substudy to investigate the steady-state plasma PK of SQV in this group of 14 subjects was scheduled after 12 to 26 weeks of taking continuous once-daily SQV SGC/RTV, 1600/100 mg, on the STI trial and two NRTIs. This sample size is sufficient for performing bioequivalence studies according to FDA guidelines (see www.fda.gov).
The subjects were designated to take 1 week of once-daily SQV HGC plus RTV, 1600/100 mg, and NRTIs, followed by steady-state SQV PK determinations. They then took once-daily SQV SGC plus RTV, 1600/100 mg, with NRTIs for 1 week, followed again by steadystate SQV PK determinations. After an overnight fast, subjects ingested 1600 mg of SQV SGC or SGC HGC plus 100 mg of RTV with breakfast (10-15 g of fat, 400-700 kcal) on their PK evaluation day. On both PK days, blood samples were drawn just before ingestion of the drugs and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 hours after ingestion. Plasma was isolated by centrifugation (900g for 10 minutes) on the same day and stored at −20°C until analysis.
Analysis of Plasma Samples
Plasma concentrations of SQV were analyzed with a sensitive and selective reversed-phase high-performance liquid chromatographic assay with ultraviolet detection at the University Medical Center Nijmegen, Nijmegen, The Netherlands (12).
Pharmacokinetic Analysis
Plasma concentration (C) versus time (t) data of SQV were analyzed by a combination compartmental and noncompartmental method. The highest observed plasma concentration was defined C max , with the corresponding sampling time as t max . The terminal log-linear period (log C versus t) was defined by the last data points (n Ն 3) by visual inspection. The absolute value of the slope (␤/ln10) was calculated by least squares linear regression analysis. The concentration of SQV at 24 hours after ingestion (C min ) was extrapolated using the following equation: C min ‫ס‬ C 12h × e −␤ × 12 , where C 12h was the concentration of SQV at 12 hours after ingestion. This assumes that the final 12 hours of the SQV elimination curve is log-linear with a constant elimination rate. The half-life (t 1/2 ) was calculated by the equation: t 1/2 ‫ס‬ ln2/␤. The area under the plasma concentration versus time curve from 0 to 24 hours (AUC 0-24h ) was estimated using the linear trapezoidal rule from 0 to 12 hours (AUC 0-12h ) and the log-linear trapezoidal rule from 12 to 24 hours (AUC 12-24h ). The AUC 0-24h was calculated as the sum of the AUC 0-12h and the AUC 12-24h .
Statistical Analysis
Statistical calculations were performed using the Statistical Product and Service Solutions (SPSS) for Windows, version 9.0 (SPSS, Chicago, IL, U.S.A.). Bioequivalence was tested by a two-sided t test of the geometric mean ratios (GMRs) of the AUC. SQV SGC was considered the reference formulation, and SQV HGC was considered the test formulation. Similar tests were performed for C max and C min , although the study was only powered to detect a difference in AUC. A p value of Յ.05 was considered statistically significant for all tests.
RESULTS
One subject was not evaluable because of early administration of the SQV dose before arrival at the clinic. Therefore, a total of 13 HIV-1-infected Thai subjects were evaluated in this PK substudy (7 male and 6 female, . None had evidence of abnormal liver or kidney function. Subjects did not use any comedication known to interfere with the metabolism of SQV or RTV. The only adverse advents during this brief 2-week PK study were in 1 subject having diarrhea during both PK weeks and in 1 subject having diarrhea during the week on SQV SGC.
The median (IQR) steady-state PK parameters for SQV and number of subjects with C min <0.05 mg/L are listed in Figure 1 and Table 1 . The shapes of the PK curves were broadly similar for the two formulations of SQV boosted with RTV. The subjects treated with SQV HGC/RTV achieved a slightly higher C max after a longer time interval (T max ), however. The subsequent half-lives of SQV in the two arms were then similar (3.7 and 3.6 hours), but the SQV HGC arm, starting at a higher C max , had a slightly higher C min at 24 hours after dosing.
For the SQV HGC/RTV phase of the trial, the 24-hour AUC was 50 mg/h/L compared with a value of 35.5 mg/h/L for the SQV SGC/RTV phase, a result at borderline significance (p ‫ס‬ .056). The mean C max levels did not differ significantly between the groups (p ‫ס‬ .251), and there was no significant difference in C min (p ‫ס‬ .168). The GMRs show that there is not a significant difference in the PK parameters (AUC, C min , and C max ) between the SQV HGC and SQV SGC formulations (p values ‫ס‬ .056, .251, and .168, respectively; Table 2 ).
There was a 109-fold intersubject variation in the C min of SQV on SQV HGC and a 33-fold intersubject variation in the C min of SQV on SQV SGC. The C min was below 0.05 mg/L in 2 of 13 (15.4%) subjects on the SQV HGC formulation (C min ‫ס‬ 0.01 and <0.025 mg/L) and in 4 of 13 (30.8%) subjects on the SQV SGC formulation (C min ‫ס‬ 0.03, 0.04, 0.04, and 0.04 mg/L). The large variability in SQV PK precluded the possibility of de-
FIG. 1.
The median (and range) steady-state plasma concentration versus time curve of saquinavir (SQV) soft-gelatin capsules (SGCs) and SQV hard-gelatin capsules (HGCs) as measured after simultaneous ingestion of SQV SGCs or SQV HGCs, 1600 mg, plus ritonavir, 100 mg, once daily in 13 HIV-1-infected subjects. The 24-hour point is an extrapolated value.
TABLE 1. Median (interquartile range) pharmacokinetic parameters of saquinavir (SQV) soft gelatin capsules (SGC) and SQV hard-gelatin capsules (HGC) as measured after simultaneous ingestion of SQV soft-gel capsules or SQV hard-gel capsules 1600 mg plus ritonavir 100 mg once daily in 13 HIV-1-infected subjects
Subjects (N ‫ס‬ 13) The median (IQR) steady-state pharmacokinetic parameters for SQV are listed along with the number of subjects on SQV-HGC and SQV-SGC with C mins < 0.05 mg/L. AUC 0-24h , area under the plasma concentration versus time curve from 0 to 24 h; C max , maximal concentration; C min , minimal concentration at 24 h postdose; t max , time to reach C max t 1/2 , plasma elimination half-life. tecting small differences in SQV exposure in this trial. In fact, we only had 50% power to demonstrate that the observed difference of 40.8% in the median AUC values was statistically significant (p < .05, two-sided test).
DISCUSSION
Once-daily SQV HGC, 1600 mg, boosted with oncedaily RTV, 100 mg, resulted in PK parameters that are similar to those observed with once-daily SQV SGC, 1600 mg, with RTV. There were no significant differences in adverse events. The intersubject variability resulted in 4 of 13 (30.8%) subjects on the SQV SGC formulation and 2 of 13 (15.4%) subjects on the SQV HGC formulation having a C min below 0.05 mg/L. Whereas a low C min below 0.05 mg/L can indicate inadequate plasma SQV levels to suppress HIV-1 viral replication, this threshold is a conservative figure based on the use of thrice-daily SQV SGC without pharmacoenhancement with RTV (13) . The target C min may be lower than 0.05 mg/L with SQV boosted with RTV, but this needs to be evaluated.
The SQV HGC formulation differs from the SQV SGC formulation in terms of bioavailability, capsule size, need for refrigeration, drug costs, and possible tolerability. Although the bioavailability of unboosted SQV HGC is poor, this study shows that the PK data of RTVboosted SQV HGC are not statistically different from the boosted PK parameters of SQV SGC. Subject convenience should be enhanced, because the size of the SQV HGC is smaller and this formulation does not require refrigeration. Of course, the need for refrigeration is not fully eliminated for a subject, because RTV still requires cold storage. Access to this protease inhibitor should be increased soon, because SQV HGC generic production is beginning in 2002 in Thailand. Local SQV HGC production in Thailand should result in a market price less than that of SQV SGC.
The toxicity of protease inhibitors may not only be a result of plasma drug levels but of excipients found in various capsules of protease inhibitors. Capmul (medium chain mono-and diglycerides), a stabilizer of SQV SGC, can cause gastrointestinal intolerance, including abdominal pain, nausea, vomiting, and diarrhea (9) . Because SQV HGC does not require the use of capmul for stabilization, gastrointestinal adverse effects may be decreased. RTV can also increase gastrointestinal adverse effects because it contains several excipients, including polyoxyl 35 castor oil (9) . The use of a small dose of RTV may result in additional gastrointestinal symptoms. This study may have demonstrated a difference in gastrointestinal adverse effects if the SQV HGC exposure had been longer than 1 week.
In conclusion, our PK data support the use of oncedaily SQV HGC, 1600 mg, boosted with once-daily RTV, 100 mg, to provide adequate SQV PK parameters not statistically different from those of once-daily SQV SGC, 1600 mg, boosted with once-daily RTV, 100 mg, as a convenient regimen that should be less expensive and possibly more tolerable than using the hard-gelatin formulation of SQV. These important benefits in the developing world may improve drug access, which is a major obstacle in treating HIV-infected patients. AUC, area under the plasma concentration curve; C max , maximal concentration; C min , minimal concentration at 24 h postdose; SQV, saquinavir; HGC, hard-gelatin capsules; SGC, soft-gelatin capsules; CI, confidence interval.
